Oral JAK Inhibitors Drive Time-Dependent Regrowth in Adolescent-Inclusive Alopecia Areata
This meta-analysis quantifies oral Janus kinase inhibitor efficacy and short-to-medium-term safety in moderate-to-severe alopecia areata, though pediatric-specific evidence remains thin because adolescents made up only one enrolled cohort.
JAK inhibitors boost hair regrowth in alopecia areata sufferers.
Alopecia areata results in distressing hair loss with few treatment options, especially in younger populations. Oral Janus kinase (JAK) inhibitors significantly improved hair regrowth with a higher likelihood of achieving SALT ≤10 at week 24 (OR 5.69; 95% CI 3.58-9.03) compared to placebo. While effective, the study had a limited adolescent sample, indicating a need for further pediatric-focused trials. Long-term safety remains to be fully assessed. JAK inhibitors show promising results for alopecia regrowth, also benefiting adolescents.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Morriss S, Foo CH, Lin E, Rodrigues Dias F, Kushnir-Grinbaum D, FitzGerald H, Leemaqz S, Lee S, Bhoyrul B
Citation:Morriss S, Foo CH, Lin E, et al. Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. American journal of clinical dermatology. 2026;27(5):925-943. doi:10.1007/s40257-026-01060-z
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.